Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.


The Use of B-type Natriuretic Peptide in Clinical Practice


European Cardiovascular Disease 2006;2(1):1–4

The Role of Beta Blockade in Heart Failure


European Cardiology 2005;1(1):1-6

The Treatment and Diagnosis of Decompensated Heart Failure


European Cardiovascular Disease 2006;2(1):105

Treatment of Acute Heart Failure - What We Have Learned to Date and How to Put it Into Practice


European Cardiovascular Disease 2006;2(1):100–2